© 2023 MJH Life Sciences™ and Infection Control Today. All rights reserved.
In a new study researchers have developed a two-pronged approach for targeting Ebola virus infection using linked nucleic acid (LNA) antisense oligonucleotides (ASOs) designed to interfere both genes essential for translation of Ebola virus genes and to block production of an intracellular human protein needed for the virus to enter cells. The results of using LNA ASOs to interfere with critical Ebola genes and host proteins are published in Nucleic Acid Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. publishers. The full-text article is available free on the Nucleic Acid Therapeutics website through November 11, 2018 at https://www.liebertpub.com/doi/10.1089/nat.2018.0722.
Anders NÃ¤Ã¤r, Jessica Chery, Alexandre Wagschal, and Shobha Vasudevan, of Massachusetts General Hospital Cancer Center, and Harvard Medical School, Andreas Petri and Sakari Kauppinen of Aalborg University (Denmark), and Sun-Yound Lim and James Cunningham of Brigham and Women's Hospital and Harvard Medical School coauthored the article, "Development of Locked Nucleic Acid Antisense Oligonucleotides Targeting Ebola Viral Proteins and Host Factor Niemann-Pick C1."
The researchers described the distinct applications of LNA ASOs for this application. They demonstrated effective targeting of two Ebola viral genes -NP and VP24 - which promote Ebola replication and inhibit a proper immune response against the virus, respectively. They also showed the ability to use LNA ASOs to prevent Ebola infectivity via a pathway that requires the host protein Niemann-Pick C1 (NPC1).
"This is the first application of LNA ASOs as a potential therapeutic strategy for the deadly Ebola virus, with multifarious advantages over the existing but as yet unapproved strategies," says executive editor Graham C. Parker, PhD, of the Carman and Ann Adams Department of Pediatrics at Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit.
Source: Mary Ann Liebert, Inc.